Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(23):1941-1942; doi:10.1093/jnci/92.23.1941
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Mucci, N. R.
Right arrow Articles by Pienta, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mucci, N. R.
Right arrow Articles by Pienta, K. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 23, 1941-1942, December 6, 2000
© 2000 Oxford University Press

BRIEF COMMUNICATION

Expression of Nuclear Antigen Ki-67 in Prostate Cancer Needle Biopsy and Radical Prostatectomy Specimens

Neil R. Mucci, Mark A. Rubin, Myla S. Strawderman, James E. Montie, David C. Smith, Kenneth J. Pienta

Affiliations of authors: N. R. Mucci (Division of Hematology/Oncology, Department of Internal Medicine), M. A. Rubin (Department of Pathology and Section of Urology, Department of Surgery), M. S. Strawderman (Department of Biostatistics), J. E. Montie (Section of Urology, Department of Surgery), D. C. Smith, K. J. Pienta (Division of Hematology/Oncology, Department of Internal Medicine and Section of Urology, Department of Surgery), University of Michigan, Comprehensive Cancer and Geriatrics Center, Ann Arbor.

Correspondence to: Kenneth J. Pienta, M.D., Departments of Internal Medicine and Surgery, The University of Michigan, 1500 E. Medical Center Dr., 7303 CCGC, Ann Arbor, MI 48109-0946 (e-mail: kpienta@umich.edu).

A good biomarker is defined as any test (molecular, morphometric, etc.) that adds independent information to standard prognostic indicators (e.g., pathologic evaluation or clinical stage), that can be reliably reproduced in the laboratory setting, and that aids in choosing treatment options (1). The primary objective of this study was to determine if the proliferation marker Ki-67, a nuclear antigen and molecular marker known to be associated with the progression of cancer, had significantly different levels of expression in normal prostate tissue, high-grade prostatic intraepithelial neoplasia (HGPIN), and prostate adenocarcinoma (PCA) (2. . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?